attachment
attachment

Answer the genral Pharmacology part for my MBBS professional exams and include relevant diagrams

Reading File
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Reading File
Reading File
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Here is a complete, exam-ready answer for all 16 General Pharmacology topics from your Paper I:

General Pharmacology - MBBS Professional Exam Answers


1. Advantages and Disadvantages of Different Routes of Drug Administration

Oral Route

Advantages: Safe, convenient, self-administered, economical, no sterility required Disadvantages: Slow onset, first pass metabolism reduces bioavailability, unsuitable if vomiting/unconscious, irritant drugs damage GI mucosa, food may impair absorption

Sublingual (SL) Route

Advantages: Rapid absorption, bypasses first pass metabolism (e.g., GTN tablet), quick onset Disadvantages: Unpleasant taste, only for lipid-soluble drugs, small doses only

Rectal Route

Advantages: Used when oral route unavailable (unconscious, vomiting children), partial bypass of first pass (50%) Disadvantages: Incomplete/irregular absorption, patient inconvenience

Intravenous (IV) Route

Advantages: 100% bioavailability, immediate effect, accurate titration, useful in emergencies, large volumes possible Disadvantages: Risk of infection/thrombophlebitis, irreversible - no recall, specialized personnel required, expensive

Intramuscular (IM) Route

Advantages: Faster than oral, depot preparations possible (e.g., Depo-Provera), moderately large volumes Disadvantages: Painful, risk of nerve/vessel injury, variable absorption with poor perfusion

Subcutaneous (SC) Route

Advantages: Sustained release, self-administration possible (e.g., insulin) Disadvantages: Only small volumes (max 2 mL), painful, necrosis if irritant drug

Inhalation

Advantages: Direct delivery to lungs (asthma), rapid action, low systemic side effects Disadvantages: Difficult technique (metered dose inhalers), dose difficult to control

Transdermal Route

Advantages: Sustained release, bypasses first pass metabolism, non-invasive (e.g., GTN patch, nicotine patch) Disadvantages: Slow onset, only for highly lipid-soluble drugs with low molecular weight
ROUTE COMPARISON TABLE
─────────────────────────────────────────────────────────
Route       | Onset      | Bioavail. | Examples
─────────────────────────────────────────────────────────
IV          | Seconds    | 100%      | Morphine, Lignocaine
IM          | 10-30 min  | ~75-100%  | Penicillin, Vaccines
SC          | 15-30 min  | ~75-100%  | Insulin, Heparin
Oral        | 30-90 min  | Variable  | Aspirin, Metformin
Sublingual  | 1-2 min    | High      | GTN, Buprenorphine
Rectal      | 5-30 min   | ~50%      | Diazepam, Paracetamol
Transdermal | Hours      | Moderate  | GTN, Scopolamine
Inhalation  | Minutes    | High      | Salbutamol, Steroids
─────────────────────────────────────────────────────────

2. Generic and Chemical Name of Drugs

ConceptDefinitionExample
Chemical nameFull IUPAC name describing molecular structureN-(4-hydroxyphenyl)acetamide
Generic (Non-proprietary) nameApproved official name (INN - International Nonproprietary Name)Paracetamol / Acetaminophen
Brand (Proprietary) nameManufacturer's trade nameCrocin, Tylenol
More examples:
Chemical NameGeneric NameBrand Name
2-Acetoxybenzoic acidAspirinEcosprin
7-Chloro-1,3-dihydro-1-methyl-5-phenyl-2H-benzo[e]-1,4-diazepin-2-oneDiazepamValium
1-[p-chloro-α-(2-methylbenzyl)benzyl]imidazoleClotrimazoleCandid
Exam tip: The generic name is written in lowercase; brand names start with a capital letter. Prescriptions should use generic names (INN) to avoid confusion and reduce cost.

3. Special Drug Delivery Systems Including Transdermal Drug Delivery System (TDDS)

Special Drug Delivery Systems:

1. Sustained Release (SR) / Extended Release (ER):
  • Drug released slowly over 8-12 hours
  • Reduces dosing frequency, maintains steady plasma levels
  • Example: Nifedipine SR, Metformin SR
2. Enteric-Coated Tablets:
  • Coated to resist gastric acid; dissolves in alkaline intestinal pH
  • Protects GI mucosa from irritant drugs (e.g., Aspirin EC)
  • Protects acid-labile drugs (e.g., Omeprazole)
3. Transdermal Drug Delivery System (TDDS):
STRUCTURE OF A TRANSDERMAL PATCH
┌─────────────────────────────────────┐
│  Backing layer (occlusive film)     │
├─────────────────────────────────────┤
│  Drug reservoir (gel/matrix)        │
├─────────────────────────────────────┤
│  Rate-controlling membrane          │
├─────────────────────────────────────┤
│  Contact adhesive layer             │
├─────────────────────────────────────┤
│  Release liner (peeled before use)  │
└─────────────────────────────────────┘
         ↓↓ Drug permeates skin ↓↓
    [Stratum corneum → Dermis → Capillaries]
Requirements for TDDS drugs:
  • High lipid solubility
  • Low molecular weight (<500 Da)
  • Potent (low dose required)
  • Non-irritating to skin
Examples: GTN (angina), Scopolamine (motion sickness), Nicotine (smoking cessation), Fentanyl (chronic pain), Clonidine (hypertension), Estradiol (HRT)
Advantages: Avoid first pass metabolism, sustained release, non-invasive, patient compliance, easy removal Disadvantages: Slow onset, skin irritation, expensive, limited drugs qualify
4. Liposomes: Phospholipid vesicles carrying drugs - e.g., Liposomal Amphotericin B (less nephrotoxic)
5. Nanoparticles: Sub-100 nm carriers for targeted cancer drug delivery
6. Implants: Long-term SC implants - e.g., Norplant (contraception, levonorgestrel)
7. Osmotic Pump (OROS): Laser-drilled tablet releasing drug at constant rate - e.g., Nifedipine GITS

4. Management of Anaphylactic Shock

Anaphylactic shock is a Type I hypersensitivity (IgE-mediated) systemic reaction with massive mast cell degranulation.

Immediate Steps:

  1. Stop the offending agent
  2. Call for help; place patient supine with legs elevated
  3. Adrenaline (Epinephrine) 0.5 mg IM (1:1000 solution) into anterolateral thigh - DRUG OF CHOICE
    • Repeat every 5 minutes if needed
    • Mechanism: α1 - vasoconstriction (reverses hypotension); β1 - increases heart rate/contractility; β2 - bronchodilation + inhibits mast cell degranulation
  4. Oxygen - high flow (10-15 L/min via face mask)
  5. IV access - infuse normal saline rapidly for fluid resuscitation
  6. Antihistamine - Chlorphenamine 10 mg IV (H1 blocker)
  7. Corticosteroid - Hydrocortisone 200 mg IV (prevents late-phase reaction, takes 4-6 hours)
  8. Salbutamol nebulization if bronchospasm persists
ANAPHYLAXIS MANAGEMENT SUMMARY
────────────────────────────────────────────────
IMMEDIATE: Adrenaline 0.5 mg IM (1:1000)
           ↓
OXYGEN + IV fluids (0.9% NaCl bolus)
           ↓
ANTIHISTAMINE: Chlorphenamine 10 mg IV
           ↓
STEROID: Hydrocortisone 200 mg IV
           ↓
BRONCHOSPASM: Salbutamol nebulizer
           ↓
REFRACTORY: IV Adrenaline infusion
            Glucagon (if on beta-blockers)
────────────────────────────────────────────────
Note: Antihistamines and steroids are adjuncts - adrenaline is the only life-saving drug.

5. Teratogenic Drugs

A teratogen is any agent that causes structural or functional abnormality in a developing embryo/fetus.
Most vulnerable period: Organogenesis (3rd-8th week of gestation)

FDA Pregnancy Categories (Classic Classification):

  • Category A: Safe (folic acid, levothyroxine in controlled doses)
  • Category B: Animal studies safe, no adequate human studies (e.g., Metformin)
  • Category C: Animal studies show risk, no adequate human studies (e.g., Aspirin, Furosemide)
  • Category D: Evidence of fetal risk but benefits may outweigh risks (e.g., Phenytoin, Valproate)
  • Category X: Contraindicated - risks outweigh benefits (e.g., Thalidomide, Isotretinoin, Warfarin, Methotrexate)

Important Teratogenic Drugs:

DrugTeratogenic Effect
ThalidomidePhocomelia (limb reduction defects)
Valproic acidNeural tube defects (spina bifida), facial defects
PhenytoinFetal hydantoin syndrome (cleft palate, growth retardation, nail hypoplasia)
Warfarin (1st trimester)Warfarin embryopathy (nasal hypoplasia, stippled epiphyses)
TetracyclinesYellow discoloration and hypoplasia of teeth and bones
Isotretinoin (Vit A)CNS, cardiac, and craniofacial defects
ACE Inhibitors (2nd/3rd trimester)Renal tubular dysplasia, oligohydramnios
MethotrexateFolic acid antagonist → neural tube defects, limb anomalies
Diethylstilbestrol (DES)Vaginal clear cell carcinoma in female offspring
MisoprostolMöbius syndrome
CarbamazepineNeural tube defects
LithiumEbstein's cardiac anomaly
AminoglycosidesOtotoxicity (8th nerve damage)
Mnemonic - "ABCDE WVMTL" - Always Be Careful During Every Week

6. Drug Antagonism

Antagonism = two drugs interact such that one reduces the effect of the other.

Types:

A. Pharmacological/Receptor Antagonism:
1. Competitive (Reversible) Antagonism:
  • Antagonist competes with agonist for same receptor binding site
  • Can be overcome by increasing agonist concentration
  • Shifts dose-response curve to RIGHT (parallel shift), Emax unchanged
  • Example: Atropine vs Acetylcholine; Naloxone vs Morphine; Propranolol vs Adrenaline
2. Non-competitive (Irreversible) Antagonism:
  • Antagonist binds at same or different site but cannot be displaced
  • Emax reduced (ceiling effect decreased), right shift
  • Example: Phenoxybenzamine (irreversible α-blocker)
3. Partial Agonist as Antagonist:
  • Drug with lower intrinsic activity competes with full agonist
  • Example: Buprenorphine vs Morphine
B. Physiological/Functional Antagonism:
  • Two drugs act on different receptors but produce opposing effects on same physiological endpoint
  • Example: Adrenaline (bronchodilation) antagonizes Histamine (bronchoconstriction)
C. Chemical Antagonism:
  • Direct chemical interaction neutralizes the drug
  • Example: Protamine neutralizes Heparin; Chelation therapy (EDTA for heavy metals)
D. Pharmacokinetic Antagonism:
  • One drug alters absorption, distribution, or metabolism of another
  • Example: Enzyme inducers (Rifampicin, Phenobarbitone) reduce plasma levels of co-administered drugs
DOSE-RESPONSE CURVES IN ANTAGONISM

    Effect
      |
 Emax ├─── ─ ─ ─ ─── ─ ─ ─ ─ ─ ─ ─   ← Agonist alone
      │        /
      │       /
      │   Competitive     Non-competitive
      │   antagonist      antagonist
      │      /──          /── (Emax reduced)
      └──────────────────────────────▶ Log [Dose]
      
Competitive: Parallel right shift, same Emax
Non-competitive: Right shift + Emax reduced

7. Plasma Protein Binding

Drugs circulate in blood in two forms:
  • Bound fraction (to plasma proteins - pharmacologically inactive, non-diffusible reservoir)
  • Free/unbound fraction (pharmacologically ACTIVE, able to cross membranes)

Proteins involved:

  • Albumin - binds acidic drugs (Warfarin, Phenytoin, Aspirin, Furosemide)
  • α1-acid glycoprotein (AAG) - binds basic drugs (Lidocaine, Propranolol, Quinidine)
  • Globulins - bind hormones, vitamins, iron, cortisol

Clinical Significance:

SituationEffect
Hypoalbuminaemia (liver disease, nephrotic syndrome)↑ Free drug → Toxicity at normal doses
Drug displacement from binding sitesTransient ↑ free drug (quickly cleared)
NeonatesLow albumin → Higher free drug fraction
Only FREE drug:
  • Crosses blood-brain barrier
  • Is filtered at glomerulus
  • Is metabolized by liver
  • Exerts pharmacological effect
  • Is measured by volume of distribution
Highly protein-bound drugs (>90%): Warfarin (99%), Phenytoin (90%), Diazepam (98%), Furosemide (99%)
Note (Katzung): Displacement from protein binding alone rarely causes clinically significant interactions because the displaced drug is immediately redistributed and eliminated. The interaction is clinically relevant only if the displacing drug also inhibits clearance.

8. First Pass Metabolism

Definition: The metabolism of a drug that occurs in the gut wall and liver before it enters the systemic circulation, following oral administration.

Pathway:

ORAL DRUG → GI Lumen → Gut Wall (CYP3A4) → Portal Vein
                                                    ↓
                               Liver (CYP450 enzymes)
                                        ↓
                        SYSTEMIC CIRCULATION (reduced amount)

Result:

  • Only a fraction of the administered dose reaches systemic circulation
  • This reduces bioavailability

Drugs with High First Pass Effect (>70% extraction):

  • Morphine (oral bioavailability ~25%)
  • Propranolol (oral bioavailability ~25%)
  • Lidocaine (given IV only for arrhythmia - ~3% oral bioavailability)
  • GTN (oral bioavailability <1%)
  • Aspirin
  • Salbutamol (significant)
  • Testosterone (extensive first pass → use methyltestosterone or patches)

Ways to Bypass First Pass:

  • Sublingual (GTN tablet)
  • Transdermal (GTN patch)
  • Rectal (partial bypass ~50%)
  • Parenteral (IM, IV, SC)
  • Inhalation

Factors affecting first pass:

  • Blood flow to liver (reduced in liver disease → ↑ bioavailability of high extraction drugs)
  • Enzyme induction/inhibition
  • Gut wall metabolism (CYP3A4)

9. Bioavailability

Definition: The fraction (proportion) of administered drug dose that reaches the systemic circulation in an unchanged, pharmacologically active form.
Formula:
Bioavailability (F) = AUC oral / AUC IV × 100%

AUC = Area Under the Plasma Concentration-Time Curve
PLASMA CONCENTRATION - TIME CURVE

Plasma
conc.   ┤
(Cp)    │         ╭─────╮
        │        /       \        ← IV (AUC = 100%)
        │       /         \
        │      /     ╭─────╮
        │     /     /       \     ← Oral (AUC < 100%)
        │    /     /         \
        └───┴─────────────────▶ Time
                Tmax

Absolute vs Relative Bioavailability:

  • Absolute: Compared to IV (100%) - true F value
  • Relative: Compared to another oral formulation (reference standard)

Factors Affecting Bioavailability:

  1. Route of administration (IV = 100%)
  2. First pass metabolism (reduces oral bioavailability)
  3. Gut motility (faster = less absorption)
  4. Food (can increase or decrease)
  5. Drug formulation (particle size, excipients)
  6. Drug solubility and dissolution
  7. Liver/gut wall enzyme activity
  8. Drug-drug interactions (e.g., antacids reduce absorption of fluoroquinolones)
RouteApproximate Bioavailability
IV100%
IM75-100%
Oral5-100% (variable)
Sublingual50-75% (bypasses first pass)
Rectal~50%
TransdermalVariable (low to moderate)

10. Why is Omeprazole Given on an Empty Stomach in the Morning?

This is a classic exam question with a detailed pharmacological explanation:

Mechanism of Action of Omeprazole:

  • Omeprazole is a Proton Pump Inhibitor (PPI)
  • It is a prodrug - converted to active sulphenamide in acidic canalicular pH of parietal cells
  • Active form irreversibly inhibits H+/K+ ATPase (the proton pump) on the luminal surface of parietal cells

Why empty stomach?

1. Acid-labile nature:
  • Omeprazole is unstable in gastric acid (degrades at low pH)
  • Taken as enteric-coated capsule to protect from gastric acid
  • The enteric coating dissolves in the small intestine (alkaline pH)
2. Proton pumps must be ACTIVE to be inhibited:
  • Omeprazole only inhibits pumps that are actively secreting acid
  • Maximum number of active proton pumps are present after fasting (especially overnight fast)
  • After meals, many pumps are already cycling/synthesizing
  • Fasting → pumps recruited to canalicular membrane → ready to be inhibited
3. Morning dosing:
  • After overnight fast, most pumps are active in the morning
  • A meal after taking omeprazole stimulates acid secretion and activates the pumps
  • Omeprazole is then present in bloodstream to inhibit these active pumps
  • Optimal: Take 30-60 minutes BEFORE breakfast
SEQUENCE FOR MAXIMUM EFFECT:
 
Overnight fast  →  Proton pumps recruited
      ↓
Take Omeprazole (30-60 min before breakfast)
      ↓
Omeprazole absorbed from small intestine
      ↓
Circulates to parietal cell → converted to sulphenamide
      ↓
Eat breakfast → Stimulates acid secretion → Pumps activated
      ↓
Active sulphenamide irreversibly binds active H+/K+ ATPase
      ↓
Maximum acid suppression achieved
Key point: Evening/bedtime dosing is LESS effective because nocturnal acid secretion does not involve maximum pump recruitment. However, for nocturnal symptoms/GERD, twice-daily dosing is used.

11. Zero Order and First Order Kinetics

First Order Kinetics (Exponential):

  • A constant FRACTION (%) of the drug is eliminated per unit time
  • Rate of elimination is proportional to drug concentration
  • At higher concentration → faster elimination (but same fraction)
  • Produces a straight line on semi-log plot
  • Has a constant half-life
  • Most drugs at therapeutic concentrations follow first order kinetics
FIRST ORDER: Cp vs Time (Semi-log)

Log Cp |  ─────────
       │           ────────────
       │                        ────────
       └────────────────────────────────▶ Time
                 (STRAIGHT LINE)

Zero Order Kinetics (Linear):

  • A constant AMOUNT of drug is eliminated per unit time
  • Occurs when elimination mechanisms are saturated (capacity-limited)
  • Rate does NOT depend on concentration (fixed amount per hour)
  • Produces a straight line on linear plot
  • Half-life is NOT constant - increases as concentration rises
  • Small dose changes → disproportionately large changes in plasma level (DANGEROUS)
ZERO ORDER: Cp vs Time (Linear)

Cp     |  ────────────────────────────────
       │                                   ─────────
       └────────────────────────────────────────────▶ Time
                 (STRAIGHT LINE on linear plot)

Drugs showing zero order at therapeutic doses:

  • Phenytoin (classic example - "saturation kinetics")
  • Alcohol (Ethanol) - 10 g/hour metabolized regardless of concentration
  • Aspirin at high (anti-inflammatory) doses

Michaelis-Menten Kinetics:

Most drugs switch from first order (at low concentrations) to zero order (at high concentrations) when enzymes become saturated. This is described by Michaelis-Menten equation:
v = Vmax × C / (Km + C)

Vmax = maximum elimination rate
Km = concentration at half-Vmax (Michaelis constant)
C = drug concentration

When C << Km → First order
When C >> Km → Zero order

12. Plasma Half Life (t½)

Definition: Time required for the plasma concentration of a drug to fall to half (50%) of its original value.
Formula:
t½ = 0.693 × Vd / CL

Vd = Volume of distribution
CL = Clearance
0.693 = ln2 (natural log of 2)

Significance:

  1. Time to reach steady state: ~4-5 half-lives after starting regular dosing
  2. Time for drug elimination: ~4-5 half-lives for 97% elimination
  3. Dosing interval: Usually equal to one half-life
  4. Loading dose: May be needed if t½ is long (e.g., digoxin)
HALF-LIFE CONCEPT

Plasma     100 ─────────────────────────────
Conc (%)    │
            │
         50─┤         ─────────────────────
            │
         25─┤                   ──────────
            │
        12.5┤                         ─────
            └──┬──────────┬──────────┬──────▶ Time
               t½         2t½        3t½
ACCUMULATION TO STEADY STATE
% Steady   │
state      │                         ─────────── 100%
achieved   │                  ───────
           │           ───────
           │     ──────
           └──────────────────────────────▶
                 1    2    3    4    5  (number of t½)

Clinical Examples:

DrugClinical Implication
Digoxin36 hoursOnce daily dosing; takes ~1 week to steady state
Aspirin15-20 min (metabolite 4-6 hr)
Warfarin36-42 hoursINR takes 3-4 days to stabilize
Penicillin G30 min4-6 hourly dosing needed
Amiodarone40-55 daysVery long - drug interaction concerns
ThiopentoneShort distribution t½ (short action) but long elimination t½Cumulation on repeated dosing

13. Therapeutic Drug Monitoring (TDM)

Definition: Measurement of drug concentrations in biological fluids (usually plasma) to optimize drug therapy by maintaining levels within the therapeutic window.

Therapeutic Window:

THERAPEUTIC WINDOW

Plasma   │            ─────────────────────  ← TOXIC LEVEL
conc.    │           / Toxic range
         │──────────/──────────────────────  ← MTC (Minimum Toxic Conc.)
         │         /  THERAPEUTIC WINDOW
         │────────/──────────────────────── ← MEC (Minimum Effective Conc.)
         │       / Subtherapeutic
         └──────────────────────────────────▶ Time

Indications for TDM:

  • Narrow therapeutic index drugs (small difference between effective and toxic dose)
  • Non-linear pharmacokinetics (Phenytoin)
  • High inter-individual variability (due to genetics, disease)
  • Serious adverse effects (aminoglycosides - nephrotoxicity/ototoxicity)
  • Suspected non-compliance
  • Suspected toxicity
  • Altered drug handling (renal/hepatic disease)

Drugs routinely monitored:

DrugTherapeutic RangeReason
Digoxin0.8-2 ng/mLNarrow TI, toxicity common
Phenytoin10-20 μg/mLZero order kinetics, toxicity
Lithium0.6-1.2 mEq/LNarrow TI, serious toxicity
AminoglycosidesPeak: 5-10 μg/mL; Trough: <2 μg/mLNephro/ototoxicity
VancomycinTrough: 10-20 μg/mLToxicity
Carbamazepine4-12 μg/mLNTI
Valproate50-100 μg/mLNTI
Cyclosporin100-400 ng/mLNephrotoxicity
Theophylline10-20 μg/mLNarrow TI
Methotrexate<1 μmol/L at 48 hrsHigh-dose MTX toxicity
When to sample: At steady state (after 4-5 t½), trough level (just before next dose) for most drugs.

14. Fixed Dose Combination (FDC)

Definition: A product containing two or more active pharmaceutical ingredients (APIs) combined in a fixed ratio in a single dosage form.

Rationale / Advantages:

AdvantageExample
Synergistic effect - enhanced efficacyCo-trimoxazole (Trimethoprim + Sulfamethoxazole)
Reduced adverse effects (lower doses of each)Levodopa + Carbidopa (Carbidopa prevents peripheral L-DOPA conversion, reducing nausea)
Improved compliance (fewer tablets)Anti-TB regimens (HRZE), HIV HAART (Tenofovir + Emtricitabine + Efavirenz = Atripla)
Delay in drug resistance (anti-TB, HIV)Anti-TB four-drug FDC
Convenience and cost-effectivenessAntihypertensive combinations (Telmisartan + Amlodipine)

Disadvantages:

  • Cannot adjust dose of individual component
  • If side effect occurs, can't identify which drug
  • Pharmacokinetic incompatibility possible
  • Regulatory challenges

Examples:

FDCComponentsUse
AugmentinAmoxicillin + Clavulanic acidAntibacterial
Co-trimoxazoleTrimethoprim + SulfamethoxazoleUTI, PCP
SinemetLevodopa + CarbidopaParkinson's disease
LodozBisoprolol + HCTZHypertension
CombivirZidovudine + LamivudineHIV
KaletraLopinavir + RitonavirHIV

15. Clinical Trials

A clinical trial is a prospective biomedical or behavioral research study in human participants to evaluate interventions for new drugs/devices.

Phases of Clinical Trials:

PHASES OF CLINICAL TRIALS
─────────────────────────────────────────────────────────────────────────
PHASE 0 (Microdosing)
- <10 subjects (healthy volunteers)
- Sub-therapeutic dose (<1% of pharmacological dose)
- PK studies, target binding - NO therapeutic intent
─────────────────────────────────────────────────────────────────────────
PHASE I (First in Human)
- 20-100 HEALTHY VOLUNTEERS
- SAFETY, tolerance, PK, dose range finding
- Maximum tolerated dose determined
─────────────────────────────────────────────────────────────────────────
PHASE II (Pilot Efficacy)
- 100-300 PATIENTS with target disease
- EFFICACY and SAFETY
- Dose optimization
- Double-blind, placebo-controlled
─────────────────────────────────────────────────────────────────────────
PHASE III (Definitive Efficacy / Pivotal)
- 300-3000+ patients (multicenter, multinational)
- Compare with STANDARD TREATMENT
- Confirm efficacy, safety, ADR profile
- RANDOMIZED CONTROLLED TRIAL (RCT)
- Basis for regulatory approval (FDA, CDSCO)
─────────────────────────────────────────────────────────────────────────
PHASE IV (Post-marketing Surveillance)
- ENTIRE POPULATION using the drug post-approval
- Rare ADRs (not detected in Phase III), long-term safety
- PHARMACOVIGILANCE
- Drug may be withdrawn here (e.g., Rofecoxib/Vioxx)
─────────────────────────────────────────────────────────────────────────

Study Design Terms:

  • Randomization: Participants randomly assigned to groups (eliminates selection bias)
  • Blinding: Single-blind (patient unaware), Double-blind (patient + investigator unaware), Triple-blind (+ statistician)
  • Placebo: Inert substance identical in appearance to test drug
  • Crossover: Each patient receives both treatments sequentially
  • Informed consent: Mandatory ethical requirement

16. Adverse Drug Reactions (ADR)

Definition: Any noxious, unintended, and undesired effect of a drug that occurs at doses used in humans for prophylaxis, diagnosis, or therapy. (WHO definition)

Classification (Rawlins & Thompson - Type A & B):

Type A (Augmented) - PREDICTABLE, dose-dependent:
  • Extension of pharmacological effect
  • Most common (80% of ADRs)
  • Example: Bleeding with Warfarin, Hypoglycemia with Insulin, Bradycardia with Propranolol
Type B (Bizarre) - UNPREDICTABLE, dose-independent:
  • Not related to pharmacological action
  • Immunological (allergy) or genetic (idiosyncratic) mechanisms
  • Example: Anaphylaxis with Penicillin, Aplastic anemia with Chloramphenicol, Malignant hyperthermia with Succinylcholine
Type C (Chronic): Occur with prolonged use - e.g., Adrenal suppression with long-term steroids
Type D (Delayed): Appear long after drug exposure - e.g., Carcinogenesis (DES), Teratogenicity
Type E (End of treatment): Withdrawal reactions - e.g., Opioid withdrawal, Rebound hypertension with Clonidine
Type F (Failure): Unexpected failure of therapy - e.g., Resistance

Grading of ADR Severity:

  • Mild: No therapy required, not disabling (e.g., mild nausea)
  • Moderate: Requires change in therapy (e.g., rash)
  • Severe: Life-threatening, requires hospitalization (e.g., Stevens-Johnson syndrome, anaphylaxis)

Pharmacovigilance:

  • The science of monitoring drug safety post-marketing
  • Yellow Card Scheme (UK) / MedWatch (USA) / PVPI (India) - systems for ADR reporting
  • Naranjo Algorithm - tool to assess causality of ADR (Definite/Probable/Possible/Doubtful)

Common ADR Examples:

DrugADR
ACE inhibitorsDry cough (bradykinin accumulation)
AminoglycosidesNephrotoxicity, Ototoxicity
ChloramphenicolAplastic anemia, Grey baby syndrome
MetforminLactic acidosis
StatinsMyopathy, Rhabdomyolysis
QuinolonesTendon rupture, QT prolongation
ClozapineAgranulocytosis
HalothaneHepatitis
SulfonamidesStevens-Johnson syndrome

References: Katzung's Basic and Clinical Pharmacology 16e; Goodman & Gilman's Pharmacological Basis of Therapeutics; KD Tripathi's Essentials of Medical Pharmacology
Study tip for exams: Topics 8, 9, 11, 12 often come together as linked questions on pharmacokinetics. ADR classification (Type A-F), anaphylaxis management, and teratogenic drugs are high-yield short answer/essay topics. Always draw labeled diagrams for dose-response curves, half-life curves, and the transdermal patch structure.

Create a PDF cheat sheet with all 16 General Pharmacology topics

Reading File
Running Command

ls -la /tmp/workspace/ 2>/dev/null || mkdir -p /tmp/workspace && echo "workspace ready"

Running Command

mkdir -p /tmp/workspace/pharmacology-cheatsheet && cat > /tmp/workspace/pharmacology-cheatsheet/gen_pdf.py << 'PYEOF' from reportlab.lib.pagesizes import A4 from reportlab.lib import colors from reportlab.lib.styles import getSampleStyleSheet, ParagraphStyle from reportlab.lib.units import cm, mm from reportlab.platypus import (SimpleDocTemplate, Paragraph, Spacer, Table, TableStyle, HRFlowable, KeepTogether, PageBreak) from reportlab.lib.enums import TA_CENTER, TA_LEFT, TA_JUSTIFY from reportlab.graphics.shapes import Drawing, Rect, String, Line, Polygon from reportlab.graphics import renderPDF from reportlab.platypus.flowables import Flowable import io # ─── COLOUR PALETTE ─────────────────────────────────────────────────────────── DARK_BLUE = colors.HexColor("#1A3A5C") MID_BLUE = colors.HexColor("#2E6DA4") LIGHT_BLUE = colors.HexColor("#D6E8F7") ACCENT_TEAL = colors.HexColor("#00897B") ACCENT_GREEN= colors.HexColor("#E8F5E9") WARN_RED = colors.HexColor("#C62828") WARN_YELLOW = colors.HexColor("#FFF9C4") WARN_BORDER = colors.HexColor("#F9A825") GRAY_BG = colors.HexColor("#F5F5F5") DARK_TEXT = colors.HexColor("#212121") TABLE_HEAD = colors.HexColor("#1A3A5C") TABLE_ALT = colors.HexColor("#EBF3FB") BOX_BG = colors.HexColor("#E3F2FD") BOX_BORDER = colors.HexColor("#1565C0") ORANGE_BG = colors.HexColor("#FFF3E0") ORANGE_BDR = colors.HexColor("#E65100") W, H = A4 # 595.27 x 841.89 pts # ─── STYLES ─────────────────────────────────────────────────────────────────── styles = getSampleStyleSheet() def sty(name, **kw): s = ParagraphStyle(name, **kw) return s TITLE = sty("TITLE", fontName="Helvetica-Bold", fontSize=20, textColor=colors.white, spaceAfter=4, alignment=TA_CENTER) SUBTITLE = sty("SUBTITLE", fontName="Helvetica", fontSize=11, textColor=colors.HexColor("#B0C4DE"), alignment=TA_CENTER, spaceAfter=2) H1 = sty("H1", fontName="Helvetica-Bold", fontSize=13, textColor=colors.white, spaceBefore=2, spaceAfter=4) H2 = sty("H2", fontName="Helvetica-Bold", fontSize=10, textColor=DARK_BLUE, spaceBefore=6, spaceAfter=3) H3 = sty("H3", fontName="Helvetica-BoldOblique", fontSize=9, textColor=ACCENT_TEAL, spaceBefore=4, spaceAfter=2) BODY = sty("BODY", fontName="Helvetica", fontSize=8.5, textColor=DARK_TEXT, leading=13, spaceAfter=3, alignment=TA_JUSTIFY) BULLET = sty("BULLET", fontName="Helvetica", fontSize=8.5, textColor=DARK_TEXT, leading=13, leftIndent=14, firstLineIndent=-8, spaceAfter=2) SMALL = sty("SMALL", fontName="Helvetica", fontSize=7.5, textColor=colors.HexColor("#555555"), leading=11, spaceAfter=2) MONO = sty("MONO", fontName="Courier", fontSize=7.5, textColor=DARK_TEXT, leading=11, backColor=GRAY_BG, leftIndent=8, spaceAfter=2) WARN = sty("WARN", fontName="Helvetica-Bold", fontSize=8.5, textColor=WARN_RED, spaceBefore=2, spaceAfter=2) KEY = sty("KEY", fontName="Helvetica-Bold", fontSize=8.5, textColor=DARK_BLUE, spaceBefore=2, spaceAfter=2) TABLE_HEAD_S = sty("TH", fontName="Helvetica-Bold", fontSize=8, textColor=colors.white, alignment=TA_CENTER) TABLE_CELL = sty("TC", fontName="Helvetica", fontSize=8, textColor=DARK_TEXT, leading=11, alignment=TA_LEFT) TABLE_CELLC = sty("TCC", fontName="Helvetica", fontSize=8, textColor=DARK_TEXT, leading=11, alignment=TA_CENTER) def bullet(txt, indent=14): return Paragraph(f"<bullet>\u2022</bullet> {txt}", BULLET) def bold(txt): return f"<b>{txt}</b>" def it(txt): return f"<i>{txt}</i>" def col(txt, c): return f'<font color="{c}">{txt}</font>' def hdr(p, text): """Section header with coloured background.""" d = Drawing(W - 3*cm, 20) d.add(Rect(0, 0, W - 3*cm, 18, fillColor=DARK_BLUE, strokeColor=None)) d.add(String(8, 5, text, fontName="Helvetica-Bold", fontSize=11, fillColor=colors.white)) p.append(d) p.append(Spacer(1, 4)) def subhdr(text): d = Drawing(W - 3*cm, 16) d.add(Rect(0, 0, W - 3*cm, 15, fillColor=MID_BLUE, strokeColor=None)) d.add(String(6, 4, text, fontName="Helvetica-Bold", fontSize=9.5, fillColor=colors.white)) return d def box(content_list, bg=BOX_BG, border=BOX_BORDER): """Wrap a list of flowables in a coloured box via Table.""" inner = [Spacer(1,4)] + content_list + [Spacer(1,4)] t = Table([[inner]], colWidths=[W - 3.2*cm]) t.setStyle(TableStyle([ ("BACKGROUND", (0,0), (-1,-1), bg), ("BOX", (0,0), (-1,-1), 1, border), ("LEFTPADDING", (0,0), (-1,-1), 8), ("RIGHTPADDING", (0,0), (-1,-1), 8), ("TOPPADDING", (0,0), (-1,-1), 2), ("BOTTOMPADDING", (0,0), (-1,-1), 4), ])) return t def std_table(headers, rows, col_widths=None): data = [[Paragraph(h, TABLE_HEAD_S) for h in headers]] for row in rows: data.append([Paragraph(str(c), TABLE_CELL) for c in row]) if not col_widths: n = len(headers) col_widths = [(W - 3.2*cm)/n] * n t = Table(data, colWidths=col_widths, repeatRows=1) style = [ ("BACKGROUND", (0,0), (-1,0), TABLE_HEAD), ("TEXTCOLOR", (0,0), (-1,0), colors.white), ("ROWBACKGROUNDS", (0,1), (-1,-1), [colors.white, TABLE_ALT]), ("GRID", (0,0), (-1,-1), 0.4, colors.HexColor("#BBBBBB")), ("LEFTPADDING", (0,0), (-1,-1), 5), ("RIGHTPADDING", (0,0), (-1,-1), 5), ("TOPPADDING", (0,0), (-1,-1), 3), ("BOTTOMPADDING", (0,0), (-1,-1), 3), ("VALIGN", (0,0), (-1,-1), "TOP"), ] t.setStyle(TableStyle(style)) return t def two_col(left_items, right_items): """Two-column layout.""" cw = (W - 3.4*cm) / 2 - 4 left_t = Table([[f] for f in left_items], colWidths=[cw]) right_t = Table([[f] for f in right_items], colWidths=[cw]) left_t.setStyle(TableStyle([("LEFTPADDING",(0,0),(-1,-1),0),("RIGHTPADDING",(0,0),(-1,-1),0),("TOPPADDING",(0,0),(-1,-1),0),("BOTTOMPADDING",(0,0),(-1,-1),0)])) right_t.setStyle(TableStyle([("LEFTPADDING",(0,0),(-1,-1),0),("RIGHTPADDING",(0,0),(-1,-1),0),("TOPPADDING",(0,0),(-1,-1),0),("BOTTOMPADDING",(0,0),(-1,-1),0)])) outer = Table([[left_t, right_t]], colWidths=[cw+4, cw+4]) outer.setStyle(TableStyle([ ("LEFTPADDING",(0,0),(-1,-1),0),("RIGHTPADDING",(0,0),(-1,-1),0), ("TOPPADDING",(0,0),(-1,-1),0),("BOTTOMPADDING",(0,0),(-1,-1),0), ("VALIGN",(0,0),(-1,-1),"TOP"), ])) return outer # ─── ASCII DIAGRAM HELPER ────────────────────────────────────────────────────── def ascii_box(lines, bg=GRAY_BG): content = [Paragraph(line, MONO) for line in lines] return box(content, bg=bg, border=colors.HexColor("#90A4AE")) # ══════════════════════════════════════════════════════════════════════════════ # BUILD DOCUMENT # ══════════════════════════════════════════════════════════════════════════════ out_path = "/tmp/workspace/pharmacology-cheatsheet/General_Pharmacology_Cheatsheet.pdf" doc = SimpleDocTemplate(out_path, pagesize=A4, leftMargin=1.5*cm, rightMargin=1.5*cm, topMargin=1.5*cm, bottomMargin=1.5*cm) story = [] # ───────────────────────────────────────────────────────────────────────────── # COVER HEADER # ───────────────────────────────────────────────────────────────────────────── cover_table = Table( [[Paragraph("GENERAL PHARMACOLOGY", TITLE)], [Paragraph("MBBS Professional Exam Cheat Sheet | All 16 Topics", SUBTITLE)]], colWidths=[W - 3*cm] ) cover_table.setStyle(TableStyle([ ("BACKGROUND", (0,0), (-1,-1), DARK_BLUE), ("TOPPADDING", (0,0), (-1,-1), 10), ("BOTTOMPADDING", (0,0), (-1,-1), 10), ("LEFTPADDING", (0,0), (-1,-1), 12), ])) story.append(cover_table) story.append(Spacer(1, 8)) # INDEX index_data = [ ["1. Routes of Administration", "2. Generic & Chemical Names", "3. Special Drug Delivery / TDDS"], ["4. Anaphylactic Shock", "5. Teratogenic Drugs", "6. Drug Antagonism"], ["7. Plasma Protein Binding", "8. First Pass Metabolism", "9. Bioavailability"], ["10. Omeprazole – Empty Stomach", "11. Zero & First Order Kinetics", "12. Plasma Half-Life"], ["13. Therapeutic Drug Monitoring", "14. Fixed Dose Combination", "15. Clinical Trials"], ["16. Adverse Drug Reactions", "", ""], ] idx_t = Table(index_data, colWidths=[(W-3*cm)/3]*3) idx_t.setStyle(TableStyle([ ("BACKGROUND", (0,0), (-1,-1), LIGHT_BLUE), ("TEXTCOLOR", (0,0), (-1,-1), DARK_BLUE), ("FONTNAME", (0,0), (-1,-1), "Helvetica"), ("FONTSIZE", (0,0), (-1,-1), 8), ("GRID", (0,0), (-1,-1), 0.3, MID_BLUE), ("LEFTPADDING", (0,0), (-1,-1), 6), ("TOPPADDING", (0,0), (-1,-1), 4), ("BOTTOMPADDING", (0,0), (-1,-1), 4), ])) story.append(idx_t) story.append(Spacer(1, 10)) # ════════════════════════════════════════════════════════════════════════ # TOPIC 1 – Routes of Administration # ════════════════════════════════════════════════════════════════════════ hdr(story, "1. ROUTES OF DRUG ADMINISTRATION") routes = [ ["Route", "Onset", "Bioavail.", "Advantages", "Disadvantages", "Examples"], ["IV", "Seconds", "100%", "Immediate, accurate titration, large vol.", "Irreversible, infection risk, skilled staff", "Morphine, Lignocaine"], ["IM", "10–30 min", "75–100%", "Faster than oral, depot possible", "Painful, nerve injury risk", "Penicillin, Vaccines"], ["SC", "15–30 min", "75–100%", "Sustained release, self-admin", "Small vol only (<2 mL), necrosis risk", "Insulin, Heparin"], ["Oral", "30–90 min", "Variable", "Safe, cheap, convenient", "First-pass, food interactions, slow", "Metformin, Aspirin"], ["Sublingual", "1–2 min", "High", "Bypasses first pass, rapid", "Small doses only, taste", "GTN, Buprenorphine"], ["Rectal", "5–30 min", "~50%", "Useful if vomiting/unconscious", "Irregular absorption, inconvenient", "Diazepam, Paracetamol"], ["Transdermal", "Hours", "Moderate", "Bypass first pass, sustained, non-invasive", "Slow onset, skin irritation", "GTN patch, Nicotine patch"], ["Inhalation", "Minutes", "High (local)", "Direct lung delivery, low systemic SE", "Difficult technique", "Salbutamol, Beclometasone"], ] story.append(std_table(routes[0], routes[1:], col_widths=[1.8*cm, 1.4*cm, 1.4*cm, 3.8*cm, 3.8*cm, 3.3*cm])) story.append(Spacer(1, 6)) # ════════════════════════════════════════════════════════════════════════ # TOPIC 2 – Generic & Chemical Names # ════════════════════════════════════════════════════════════════════════ hdr(story, "2. GENERIC AND CHEMICAL NAMES OF DRUGS") story.append(two_col( [ Paragraph(bold("Definitions"), H2), bullet("<b>Chemical name:</b> Full IUPAC structure name"), bullet("<b>Generic (INN) name:</b> Official non-proprietary name – used in prescriptions"), bullet("<b>Brand name:</b> Manufacturer's trade name (capital letter)"), Spacer(1,4), Paragraph(bold("Rule:") + " Prescriptions should always use <b>generic (INN)</b> names – reduces cost, prevents confusion", BODY), ], [ Paragraph(bold("Examples"), H2), std_table( ["Chemical Name", "Generic Name", "Brand"], [ ["2-Acetoxybenzoic acid", "Aspirin", "Ecosprin"], ["N-(4-hydroxyphenyl)acetamide", "Paracetamol", "Crocin"], ["7-Chloro-1,3-dihydro-1-methyl-5-phenyl-2H-1,4-benzodiazepin-2-one", "Diazepam", "Valium"], ["(S)-Omeprazole", "Esomeprazole", "Nexium"], ], col_widths=[5.5*cm, 2.5*cm, 1.8*cm] ), ] )) story.append(Spacer(1, 8)) # ════════════════════════════════════════════════════════════════════════ # TOPIC 3 – Special Drug Delivery / TDDS # ════════════════════════════════════════════════════════════════════════ hdr(story, "3. SPECIAL DRUG DELIVERY SYSTEMS | TRANSDERMAL (TDDS)") story.append(two_col( [ Paragraph(bold("Types of Special Delivery Systems"), H2), bullet("<b>SR/ER tablets:</b> Sustained release over 8–12 h (Nifedipine SR, Metformin XR)"), bullet("<b>Enteric-coated:</b> Resists gastric acid; dissolves at alkaline intestinal pH (Aspirin EC, Omeprazole)"), bullet("<b>OROS (osmotic pump):</b> Laser-drilled tablet, constant release (Nifedipine GITS)"), bullet("<b>Liposomes:</b> Phospholipid vesicles – targeted delivery (Liposomal Amphotericin B)"), bullet("<b>Nanoparticles:</b> <500 nm carriers – cancer targeting"), bullet("<b>Implants:</b> Long-term SC; Norplant (levonorgestrel 5 yr)"), Spacer(1,4), Paragraph(bold("TDDS Drug Requirements"), H2), bullet("High <b>lipid solubility</b>"), bullet("Low MW (<500 Da)"), bullet("Low effective dose (potent)"), bullet("Non-irritating to skin"), Spacer(1,4), Paragraph(bold("TDDS Examples"), H2), std_table(["Drug","Indication"],[ ["GTN","Angina"],["Scopolamine","Motion sickness"], ["Nicotine","Smoking cessation"],["Fentanyl","Chronic pain"], ["Clonidine","Hypertension"],["Estradiol","HRT"], ], col_widths=[4.5*cm, 4.0*cm]), ], [ Paragraph(bold("TDDS Patch Structure"), H2), ascii_box([ "┌─────────────────────────────────┐", "│ BACKING LAYER (occlusive film) │", "├─────────────────────────────────┤", "│ DRUG RESERVOIR (gel/matrix) │", "├─────────────────────────────────┤", "│ RATE-CONTROLLING MEMBRANE │", "├─────────────────────────────────┤", "│ CONTACT ADHESIVE LAYER │", "├─────────────────────────────────┤", "│ RELEASE LINER (peel before use) │", "└─────────────────────────────────┘", " ↓↓ Drug permeates skin ↓↓", " Stratum corneum → Dermis", " → Capillaries", ]), Spacer(1,6), Paragraph(bold("Advantages vs Disadvantages"), H2), std_table(["Advantage","Disadvantage"],[ ["Avoid first-pass metabolism","Slow onset of action"], ["Sustained drug levels","Skin irritation/allergy"], ["Non-invasive","Only lipophilic drugs qualify"], ["Easy removal (stops drug delivery)","Expensive"], ["Good patient compliance","Cannot use for high-dose drugs"], ], col_widths=[4.5*cm,4.5*cm]), ] )) story.append(PageBreak()) # ════════════════════════════════════════════════════════════════════════ # TOPIC 4 – Anaphylactic Shock # ════════════════════════════════════════════════════════════════════════ hdr(story, "4. MANAGEMENT OF ANAPHYLACTIC SHOCK") story.append(box([ Paragraph(bold("Definition:") + " Life-threatening Type I (IgE-mediated) hypersensitivity reaction with systemic mast cell/basophil degranulation.", BODY), Paragraph(bold("Features:") + " Urticaria, angioedema, bronchospasm, hypotension, tachycardia, loss of consciousness.", BODY), ], bg=WARN_YELLOW, border=WARN_BORDER)) story.append(Spacer(1,4)) story.append(two_col( [ Paragraph(bold("IMMEDIATE MANAGEMENT"), H2), bullet("1. <b>STOP</b> the offending agent"), bullet("2. Lay patient flat, legs elevated (Trendelenburg)"), bullet("3. <b>ADRENALINE (Epinephrine) 0.5 mg IM</b> (1:1000) into anterolateral thigh — <b>DRUG OF CHOICE</b>"), bullet(" Repeat every 5 min if no improvement"), bullet("4. <b>Oxygen</b> 10–15 L/min via face mask"), bullet("5. <b>IV access</b> + 0.9% NaCl rapid bolus (fluid resuscitation)"), bullet("6. <b>Chlorphenamine 10 mg IV</b> (H1 antihistamine — adjunct)"), bullet("7. <b>Hydrocortisone 200 mg IV</b> (prevents late-phase — adjunct)"), bullet("8. <b>Salbutamol nebulizer</b> if bronchospasm persists"), bullet("9. Refractory: IV adrenaline infusion; <b>Glucagon</b> if on β-blockers"), ], [ Paragraph(bold("Mechanism of Adrenaline"), H2), std_table(["Receptor","Effect","Benefit"],[ ["α1","Vasoconstriction","Reverses hypotension"], ["β1","↑ HR, ↑ contractility","Treats shock"], ["β2","Bronchodilation","Relieves bronchospasm"], ["β2","↓ Mast cell degranulation","Limits mediator release"], ], col_widths=[1.8*cm,3.8*cm,3.8*cm]), Spacer(1,6), Paragraph(bold("Key Points"), H2), bullet("Adrenaline is the ONLY life-saving drug"), bullet("Antihistamines and steroids are ADJUNCTS only"), bullet("IM route preferred over IV in non-arrested patients"), bullet("Adrenaline dose in children: 0.01 mg/kg IM (max 0.5 mg)"), Spacer(1,4), box([Paragraph(bold("MNEMONIC: STOAE") + " — Stop, Trendelenburg, Oxygen, Adrenaline, Extras (fluids/steroids/antihistamine)", BODY)], bg=ACCENT_GREEN, border=ACCENT_TEAL), ] )) story.append(Spacer(1, 8)) # ════════════════════════════════════════════════════════════════════════ # TOPIC 5 – Teratogenic Drugs # ════════════════════════════════════════════════════════════════════════ hdr(story, "5. TERATOGENIC DRUGS") story.append(two_col( [ Paragraph(bold("Definition:") + " Agent causing structural/functional defect in embryo/fetus", BODY), Paragraph(bold("Most vulnerable period:") + " <b>Organogenesis (Wk 3–8)</b> — differentiation of organs", BODY), Spacer(1,4), Paragraph(bold("FDA Pregnancy Categories"), H2), std_table(["Category","Safety","Example"],[ ["A","Safe in humans","Folic acid, Thyroxine"], ["B","Safe in animals; no human data","Metformin, Amoxicillin"], ["C","Animal risk; inadequate human data","Aspirin (low dose), Furosemide"], ["D","Human fetal risk; benefit > risk","Phenytoin, Valproate, Carbamazepine"], ["X","CONTRAINDICATED in pregnancy","Thalidomide, Isotretinoin, Warfarin, MTX"], ], col_widths=[1.5*cm, 4.5*cm, 3.5*cm]), ], [ Paragraph(bold("Key Teratogenic Drugs"), H2), std_table(["Drug","Effect"],[ ["Thalidomide","Phocomelia (limb reduction)"], ["Valproic acid","Neural tube defects (spina bifida)"], ["Phenytoin","Fetal hydantoin syndrome"], ["Warfarin (T1)","Warfarin embryopathy, nasal hypoplasia"], ["Tetracyclines","Yellow teeth, bone growth inhibition"], ["Isotretinoin (Vit A)","CNS, cardiac, craniofacial defects"], ["ACE inhibitors (T2/T3)","Renal tubular dysplasia, oligohydramnios"], ["Methotrexate","Neural tube defects, limb anomalies"], ["Diethylstilbestrol","Vaginal clear cell carcinoma (daughters)"], ["Lithium","Ebstein's cardiac anomaly"], ["Aminoglycosides","Ototoxicity (CN VIII damage)"], ["Carbamazepine","Neural tube defects"], ["Misoprostol","Möbius syndrome"], ], col_widths=[4.0*cm, 5.5*cm]), ] )) story.append(PageBreak()) # ════════════════════════════════════════════════════════════════════════ # TOPIC 6 – Drug Antagonism # ════════════════════════════════════════════════════════════════════════ hdr(story, "6. DRUG ANTAGONISM") story.append(two_col( [ Paragraph(bold("Types of Antagonism"), H2), std_table(["Type","Mechanism","Key Feature","Example"],[ ["Competitive (reversible)","Competes at same receptor","Parallel right shift; Emax UNCHANGED","Naloxone vs Morphine; Atropine vs ACh"], ["Non-competitive (irreversible)","Binds same/allosteric site permanently","Emax REDUCED; right shift","Phenoxybenzamine vs Adrenaline"], ["Partial agonist","Lower intrinsic activity at receptor","Competes with full agonist","Buprenorphine vs Morphine"], ["Physiological","Opposite effects via different receptors","Different receptors, same endpoint","Adrenaline vs Histamine (bronchi)"], ["Chemical","Direct chemical neutralization","No receptor involved","Protamine vs Heparin; EDTA chelation"], ["Pharmacokinetic","Alters PK of other drug","Changes absorption/metabolism","Rifampicin (inducer) vs OCP"], ], col_widths=[2.2*cm, 3.2*cm, 2.8*cm, 3.0*cm]), ], [ Paragraph(bold("Dose-Response Curve Diagram"), H2), ascii_box([ "Effect", " |", " |───────────────────────────── Agonist alone (Emax)", " | /", " | / ───────────── Competitive antagonist", " | / (parallel right shift; same Emax)", " | /", " | / ─ ─ ─ ─ ─ ─ Non-competitive antagonist", " | / (right shift + REDUCED Emax)", " | /", " └─────────────────────────────▶ Log [Dose]", ]), Spacer(1,4), box([ Paragraph(bold("Exam Key Points:"), H2), bullet("Competitive: Right shift, SAME Emax, overcome by ↑dose"), bullet("Non-competitive: Reduced Emax, CANNOT be overcome"), bullet("Chemical antagonism has NO receptor involvement"), ], bg=ACCENT_GREEN, border=ACCENT_TEAL), ] )) story.append(Spacer(1, 8)) # ════════════════════════════════════════════════════════════════════════ # TOPIC 7 – Plasma Protein Binding # ════════════════════════════════════════════════════════════════════════ hdr(story, "7. PLASMA PROTEIN BINDING") story.append(two_col( [ Paragraph(bold("Key Concept"), H2), Paragraph("Drugs circulate as <b>bound</b> (inactive reservoir) + <b>free/unbound</b> (pharmacologically ACTIVE) fractions.", BODY), Spacer(1,4), std_table(["Protein","Binds","Examples"],[ ["Albumin","Acidic drugs","Warfarin (99%), Phenytoin (90%), Furosemide (99%), Aspirin"], ["α1-acid glycoprotein","Basic drugs","Lignocaine, Propranolol, Quinidine"], ["Globulins","Hormones, vitamins","Cortisol, Vit D, Testosterone"], ], col_widths=[3.0*cm, 3.0*cm, 3.5*cm]), Spacer(1,4), Paragraph(bold("Only FREE drug:"), H2), bullet("Crosses blood-brain barrier"), bullet("Filtered at glomerulus (renally eliminated)"), bullet("Metabolized by liver"), bullet("Exerts pharmacological effect"), bullet("Determines volume of distribution"), ], [ Paragraph(bold("Clinical Significance"), H2), std_table(["Situation","Effect"],[ ["Hypoalbuminaemia (liver disease, nephrotic syndrome)","↑ Free drug → toxicity at normal doses"], ["Drug displacement from binding sites","Transient ↑ free drug (rapidly re-equilibrates)"], ["Neonates (low albumin)","↑ Free drug fraction — adjust dose"], ["Renal failure","Uremic acids displace acidic drugs"], ], col_widths=[4.5*cm, 4.9*cm]), Spacer(1,6), box([ Paragraph(bold("Important Note (Katzung):"), WARN), Paragraph("Protein binding displacement alone rarely causes clinically significant interactions because displaced drug is quickly redistributed and eliminated. Relevant only if the displacing drug <b>also inhibits clearance</b>.", BODY), ], bg=WARN_YELLOW, border=WARN_BORDER), ] )) story.append(PageBreak()) # ════════════════════════════════════════════════════════════════════════ # TOPIC 8 – First Pass Metabolism # ════════════════════════════════════════════════════════════════════════ hdr(story, "8. FIRST PASS METABOLISM") story.append(two_col( [ Paragraph(bold("Definition:") + " Metabolism of drug in <b>gut wall + liver</b> before reaching systemic circulation after oral administration", BODY), Spacer(1,4), ascii_box([ "ORAL DRUG", " ↓", "GI Lumen", " ↓ (CYP3A4 in gut wall)", "Portal Vein", " ↓", "LIVER (CYP450 enzymes)", " ↓", "SYSTEMIC CIRCULATION", "(reduced amount — ↓ bioavailability)", ]), Spacer(1,4), Paragraph(bold("Drugs with High First Pass Effect"), H2), std_table(["Drug","Oral Bioavailability"],[ ["GTN (Glyceryl trinitrate)","< 1%"], ["Lidocaine","~ 3%"], ["Propranolol","~ 25%"], ["Morphine","~ 25%"], ["Testosterone","Very low"], ["Aspirin","~70% (partly)"], ], col_widths=[5.5*cm, 4.0*cm]), ], [ Paragraph(bold("Ways to Bypass First Pass"), H2), std_table(["Route","Example"],[ ["Sublingual","GTN tablet"], ["Transdermal","GTN patch, Estradiol patch"], ["Rectal (50% bypass)","Diazepam, Paracetamol suppository"], ["IV / IM / SC","Morphine injection"], ["Inhalation","Salbutamol MDI"], ], col_widths=[4.5*cm, 5.0*cm]), Spacer(1,6), Paragraph(bold("Factors Affecting First Pass"), H2), bullet("<b>Hepatic blood flow</b> — reduced in liver disease → ↑ bioavailability"), bullet("<b>Enzyme induction</b> (Rifampicin, Phenobarbitone) → ↓ bioavailability"), bullet("<b>Enzyme inhibition</b> (Cimetidine, Grapefruit) → ↑ bioavailability"), bullet("<b>CYP3A4</b> in gut wall — major site for pre-systemic metabolism"), bullet("<b>Cardiac output</b> — high extraction drugs are flow-dependent"), ] )) story.append(Spacer(1, 8)) # ════════════════════════════════════════════════════════════════════════ # TOPIC 9 – Bioavailability # ════════════════════════════════════════════════════════════════════════ hdr(story, "9. BIOAVAILABILITY") story.append(two_col( [ Paragraph(bold("Definition:") + " Fraction of administered dose reaching systemic circulation in pharmacologically active form", BODY), Spacer(1,4), ascii_box([ "F = (AUC_oral / AUC_IV) × 100%", "", "AUC = Area Under Plasma Conc.–Time Curve", ]), Spacer(1,4), ascii_box([ "PLASMA CONC–TIME CURVE", "Cp | ╭─────────╮", " | / \\ ← IV (100%)", " | / ╭────╮", " | / / \\ ← Oral (<100%)", " | / / \\", " └───────────────────▶ Time", " ↑ Tmax", ]), Spacer(1,4), Paragraph(bold("Absolute vs Relative Bioavailability"), H2), bullet("<b>Absolute:</b> Compared to IV (reference = 100%)"), bullet("<b>Relative:</b> Compared to another oral formulation"), ], [ Paragraph(bold("Bioavailability by Route"), H2), std_table(["Route","F (approx.)"],[ ["IV","100%"], ["IM","75–100%"], ["SC","75–100%"], ["Sublingual","50–75%"], ["Rectal","~50%"], ["Oral","5–100% (variable)"], ["Transdermal","Variable"], ], col_widths=[5*cm, 4.5*cm]), Spacer(1,6), Paragraph(bold("Factors Affecting Bioavailability"), H2), bullet("First pass metabolism (main factor for oral drugs)"), bullet("Drug solubility and dissolution rate"), bullet("Gut motility (↑ motility → ↓ absorption time)"), bullet("Food effect (can increase or decrease)"), bullet("Drug formulation (particle size, excipients)"), bullet("Drug–drug interactions (e.g., antacids + fluoroquinolones)"), bullet("Hepatic/gut wall CYP enzyme activity"), ] )) story.append(PageBreak()) # ════════════════════════════════════════════════════════════════════════ # TOPIC 10 – Omeprazole Empty Stomach # ════════════════════════════════════════════════════════════════════════ hdr(story, "10. WHY IS OMEPRAZOLE GIVEN ON EMPTY STOMACH IN THE MORNING?") story.append(two_col( [ Paragraph(bold("Mechanism of Omeprazole (PPI)"), H2), bullet("Prodrug — activated in <b>acidic canalicular pH</b> of parietal cells"), bullet("Active sulphenamide form <b>irreversibly inhibits H⁺/K⁺ ATPase</b> (proton pump)"), bullet("Proton pump must be <b>ACTIVE (secreting acid)</b> to be inhibited"), bullet("Given as <b>enteric-coated</b> capsule (unstable in gastric acid)"), Spacer(1,6), Paragraph(bold("Why Empty Stomach?"), H2), bullet("After overnight fast → maximum proton pumps recruited to canalicular membrane → ready to be inhibited"), bullet("Food intake after dosing stimulates acid secretion → activates pumps → omeprazole now present to bind them"), bullet("Timing: <b>30–60 minutes BEFORE breakfast</b> = optimal"), Spacer(1,4), box([Paragraph(bold("Note:") + " Evening dosing is LESS effective. Twice-daily dosing for nocturnal GERD.", BODY)], bg=ORANGE_BG, border=ORANGE_BDR), ], [ Paragraph(bold("Sequence for Maximum Effect"), H2), ascii_box([ "OVERNIGHT FAST", " ↓", "Proton pumps recruited to", "canalicular membrane (most active)", " ↓", "Take Omeprazole 30–60 min BEFORE", "breakfast (enteric coat dissolves", "in small intestine)", " ↓", "Absorbed → portal blood →", "parietal cell → converted to", "active SULPHENAMIDE", " ↓", "Eat breakfast → stimulates", "acid secretion → pumps ACTIVATE", " ↓", "Sulphenamide irreversibly binds", "active H⁺/K⁺ ATPase", " ↓", "MAXIMUM ACID SUPPRESSION", ]), ] )) story.append(Spacer(1, 8)) # ════════════════════════════════════════════════════════════════════════ # TOPIC 11 – Zero and First Order Kinetics # ════════════════════════════════════════════════════════════════════════ hdr(story, "11. ZERO ORDER AND FIRST ORDER KINETICS") story.append(two_col( [ Paragraph(bold("First Order Kinetics"), H2), std_table(["Feature","Detail"],[ ["Definition","Constant FRACTION (%) eliminated per unit time"], ["Graph (linear)","Exponential decline"], ["Graph (semi-log)","STRAIGHT LINE"], ["Half-life","CONSTANT"], ["When?","Most drugs at therapeutic doses"], ["Formula","dC/dt = –k × C"], ], col_widths=[3.5*cm, 6.0*cm]), Spacer(1,4), Paragraph(bold("Zero Order Kinetics"), H2), std_table(["Feature","Detail"],[ ["Definition","Constant AMOUNT eliminated per unit time"], ["Graph (linear)","STRAIGHT LINE (linear decline)"], ["Graph (semi-log)","Curved line"], ["Half-life","NOT constant (increases with dose)"], ["When?","Elimination SATURATED (capacity-limited)"], ["Danger","Small ↑ in dose → huge ↑ in plasma level"], ["Examples","Phenytoin, Ethanol, Aspirin (high dose)"], ], col_widths=[3.5*cm, 6.0*cm]), ], [ Paragraph(bold("Graphical Comparison"), H2), ascii_box([ "FIRST ORDER (semi-log plot):", "log Cp | ─────────────────────────", " │ ──────", " │ ──────", " └──────────────────────▶ Time", " (Straight line)", "", "ZERO ORDER (linear plot):", "Cp | ─────────────────────", " │ ─────", " └──────────────────────────▶ Time", " (Straight line on linear)", ]), Spacer(1,6), Paragraph(bold("Michaelis-Menten Equation"), H2), ascii_box([ "v = Vmax × C", " ─────────────", " Km + C", "", "When C << Km → FIRST ORDER", "When C >> Km → ZERO ORDER", ]), Spacer(1,4), box([ Paragraph(bold("Classic Exam Example – PHENYTOIN:"), WARN), Paragraph("Switches from first-order to zero-order at therapeutic doses. Small dose changes cause DISPROPORTIONATE plasma level changes → toxicity.", BODY), ], bg=WARN_YELLOW, border=WARN_BORDER), ] )) story.append(PageBreak()) # ════════════════════════════════════════════════════════════════════════ # TOPIC 12 – Plasma Half Life # ════════════════════════════════════════════════════════════════════════ hdr(story, "12. PLASMA HALF LIFE (t½)") story.append(two_col( [ Paragraph(bold("Definition:") + " Time for plasma concentration to fall to <b>50% of its initial value</b>", BODY), Spacer(1,4), ascii_box([ "t½ = 0.693 × Vd / CL", "", "Vd = Volume of distribution (L)", "CL = Clearance (L/h)", "0.693 = ln2", ]), Spacer(1,4), ascii_box([ "% REMAINING (half-life concept):", "After 1 t½ → 50% remains", "After 2 t½ → 25% remains", "After 3 t½ → 12.5% remains", "After 4 t½ → 6.25% remains", "After 5 t½ → ~3% remains (97% eliminated)", ]), Spacer(1,4), ascii_box([ "ACCUMULATION TO STEADY STATE:", "% SS | ─────────────── 100% (5 t½)", " | ─────── 94% (4 t½)", " | ─── 75% (3 t½)", " | 50% (2 t½)", " └─────────────────────▶ t½", ]), ], [ Paragraph(bold("Clinical Significance"), H2), std_table(["Parameter","Relationship to t½"],[ ["Steady state", "Reached after ~4–5 t½"], ["Drug elimination", "~97% eliminated after 5 t½"], ["Dosing interval", "Usually = one t½"], ["Loading dose needed", "If t½ is long (to reach SS quickly)"], ], col_widths=[3.5*cm, 5.5*cm]), Spacer(1,4), Paragraph(bold("Clinical Examples"), H2), std_table(["Drug","t½","Clinical Note"],[ ["Penicillin G","30 min","4–6 hourly dosing needed"], ["Digoxin","36 hours","Once daily; ~7 days to SS"], ["Warfarin","36–42 hours","INR 3–4 days to stabilize"], ["Phenobarbitone","4–5 days","Once daily"], ["Amiodarone","40–55 days","Very long; drug interactions linger"], ["Thiopentone","Short dist. t½","Short action; cumulation on repeat"], ], col_widths=[3.0*cm, 2.2*cm, 4.3*cm]), Spacer(1,4), box([Paragraph(bold("Vd ↑") + " → t½ ↑ (drug distributes widely, less available for elimination). " + bold("CL ↑") + " → t½ ↓ (eliminated faster).", BODY)], bg=BOX_BG, border=BOX_BORDER), ] )) story.append(Spacer(1, 8)) # ════════════════════════════════════════════════════════════════════════ # TOPIC 13 – Therapeutic Drug Monitoring # ════════════════════════════════════════════════════════════════════════ hdr(story, "13. THERAPEUTIC DRUG MONITORING (TDM)") story.append(two_col( [ Paragraph(bold("Definition:") + " Measurement of drug levels in plasma to maintain concentrations within the <b>Therapeutic Window</b>", BODY), Spacer(1,4), ascii_box([ "THERAPEUTIC WINDOW", "Cp |───────────────────── MTC (Minimum Toxic Conc.)", " | THERAPEUTIC RANGE", " |───────────────────── MEC (Min. Effective Conc.)", " | SUBTHERAPEUTIC", " └──────────────────────▶ Time", " Goal: Keep drug level BETWEEN MEC and MTC", ]), Spacer(1,4), Paragraph(bold("Indications for TDM"), H2), bullet("<b>Narrow Therapeutic Index (NTI)</b> drugs"), bullet("Non-linear pharmacokinetics (Phenytoin)"), bullet("High inter-individual variability"), bullet("Serious/irreversible toxicity risk (aminoglycosides)"), bullet("Suspected non-compliance"), bullet("Suspected toxicity"), bullet("Organ failure (renal/hepatic impairment)"), ], [ Paragraph(bold("Drugs Monitored (+ Therapeutic Ranges)"), H2), std_table(["Drug","Therapeutic Range","Main Concern"],[ ["Digoxin","0.8–2 ng/mL","Narrow TI; toxicity common"], ["Phenytoin","10–20 μg/mL","Zero-order kinetics, toxicity"], ["Lithium","0.6–1.2 mEq/L","Narrow TI; serious neurotoxicity"], ["Aminoglycosides","Peak 5–10; Trough <2 μg/mL","Nephro/ototoxicity"], ["Vancomycin","Trough 10–20 μg/mL","Nephrotoxicity"], ["Carbamazepine","4–12 μg/mL","NTI"], ["Valproate","50–100 μg/mL","NTI"], ["Theophylline","10–20 μg/mL","Narrow TI, cardiac arrhythmias"], ["Cyclosporin","100–400 ng/mL","Nephrotoxicity, rejection"], ["Methotrexate","<1 μmol/L @ 48h","High-dose toxicity"], ], col_widths=[2.8*cm, 2.8*cm, 3.9*cm]), Spacer(1,4), box([Paragraph(bold("Sampling:") + " At steady state (after 4–5 t½). Trough level (just before next dose) for most drugs. Peak and trough for aminoglycosides.", BODY)], bg=ACCENT_GREEN, border=ACCENT_TEAL), ] )) story.append(PageBreak()) # ════════════════════════════════════════════════════════════════════════ # TOPIC 14 – Fixed Dose Combination # ════════════════════════════════════════════════════════════════════════ hdr(story, "14. FIXED DOSE COMBINATION (FDC)") story.append(two_col( [ Paragraph(bold("Definition:") + " Two or more APIs combined in a <b>fixed ratio</b> in a single dosage form", BODY), Spacer(1,4), Paragraph(bold("Advantages"), H2), bullet("Synergistic effect → enhanced efficacy at lower individual doses"), bullet("Reduced adverse effects (lower doses used)"), bullet("Improved patient compliance (fewer tablets)"), bullet("Delays development of drug resistance (anti-TB, HIV)"), bullet("Convenient and cost-effective"), Spacer(1,4), Paragraph(bold("Disadvantages"), H2), bullet("Cannot adjust dose of individual component"), bullet("Cannot identify which drug caused ADR"), bullet("Pharmacokinetic incompatibility possible"), bullet("Regulatory challenges"), ], [ Paragraph(bold("Important FDC Examples"), H2), std_table(["FDC Name","Components","Use"],[ ["Augmentin","Amoxicillin + Clavulanate","Beta-lactamase producing organisms"], ["Co-trimoxazole","Trimethoprim + Sulfamethoxazole","UTI, PCP prophylaxis"], ["Sinemet","Levodopa + Carbidopa","Parkinson's disease"], ["Kaletra","Lopinavir + Ritonavir","HIV (ritonavir boosts lopinavir levels)"], ["Combivir","Zidovudine + Lamivudine","HIV"], ["Atripla","TDF + FTC + Efavirenz","HIV (once daily)"], ["Anti-TB (RHEZ)","Rifampicin + INH + Ethambutol + PZA","Tuberculosis"], ["Lodoz","Bisoprolol + HCTZ","Hypertension"], ["Glucovance","Metformin + Glibenclamide","Type 2 Diabetes"], ], col_widths=[2.4*cm, 4.0*cm, 3.1*cm]), ] )) story.append(Spacer(1, 8)) # ════════════════════════════════════════════════════════════════════════ # TOPIC 15 – Clinical Trials # ════════════════════════════════════════════════════════════════════════ hdr(story, "15. CLINICAL TRIALS") story.append(two_col( [ Paragraph(bold("Definition:") + " Prospective study in human participants evaluating a new drug/device intervention", BODY), Spacer(1,4), Paragraph(bold("Phases of Clinical Trials"), H2), std_table(["Phase","Subjects","Focus","Design"],[ ["0 (Microdosing)","<10 healthy volunteers","Sub-therapeutic PK; target binding","Observational"], ["I","20–100 healthy volunteers","SAFETY, tolerance, PK, dose range","Open label"], ["II","100–300 patients","EFFICACY + safety; dose optimization","Double-blind, placebo-controlled"], ["III (Pivotal)","300–3000+ patients","Confirm efficacy vs standard treatment","Multicenter RCT"], ["IV (Post-marketing)","General population","Rare ADRs; long-term safety","Pharmacovigilance"], ], col_widths=[1.8*cm, 3.0*cm, 3.2*cm, 3.0*cm]), Spacer(1,4), box([Paragraph(bold("Phase III is basis for regulatory approval") + " (FDA/CDSCO). Phase IV is where rare/delayed ADRs emerge — drug may be WITHDRAWN (e.g., Rofecoxib/Vioxx).", BODY)], bg=WARN_YELLOW, border=WARN_BORDER), ], [ Paragraph(bold("Key Study Design Terms"), H2), std_table(["Term","Definition"],[ ["Randomization","Random assignment to groups — eliminates selection bias"], ["Single-blind","Patient unaware of treatment allocation"], ["Double-blind","Both patient AND investigator unaware"], ["Triple-blind","Patient + investigator + statistician unaware"], ["Placebo","Inert substance identical in appearance to test drug"], ["Crossover design","Each patient receives both treatments sequentially"], ["Informed consent","Mandatory ethical requirement before enrolment"], ["ITT analysis","Intention-to-treat — all randomized patients analyzed"], ], col_widths=[3.5*cm, 5.5*cm]), Spacer(1,4), Paragraph(bold("Ethical Requirements (Declaration of Helsinki)"), H2), bullet("Informed written consent from all participants"), bullet("Independent Ethics Committee (IEC) approval"), bullet("Right to withdraw at any time without penalty"), bullet("Scientific integrity + pre-registration of trial"), ] )) story.append(PageBreak()) # ════════════════════════════════════════════════════════════════════════ # TOPIC 16 – Adverse Drug Reactions # ════════════════════════════════════════════════════════════════════════ hdr(story, "16. ADVERSE DRUG REACTIONS (ADR)") story.append(Paragraph(bold("WHO Definition:") + " Any noxious, unintended, and undesired effect of a drug occurring at doses used for prophylaxis, diagnosis, or therapy", BODY)) story.append(Spacer(1,4)) story.append(two_col( [ Paragraph(bold("Rawlins & Thompson Classification"), H2), std_table(["Type","Name","Features","Examples"],[ ["A","Augmented","Predictable; dose-dependent; ~80% of ADRs; extension of pharmacology","Bleeding (Warfarin), Hypoglycemia (Insulin), Bradycardia (Propranolol)"], ["B","Bizarre","Unpredictable; dose-independent; immunological or idiosyncratic","Anaphylaxis (Penicillin), Aplastic anemia (Chloramphenicol), Malignant hyperthermia (Succinylcholine)"], ["C","Chronic","Occur with prolonged use","Adrenal suppression (long-term steroids), Tardive dyskinesia (antipsychotics)"], ["D","Delayed","Appear long after drug exposure","Carcinogenesis (DES), Teratogenicity"], ["E","End of use","Withdrawal reactions on stopping drug","Opioid withdrawal, Rebound hypertension (Clonidine)"], ["F","Failure","Unexpected failure of therapy","Drug resistance, Subtherapeutic levels"], ], col_widths=[0.8*cm, 2.0*cm, 3.5*cm, 3.2*cm]), ], [ Paragraph(bold("ADR Severity Grading"), H2), std_table(["Grade","Features","Examples"],[ ["Mild","No therapy needed, not disabling","Mild nausea, dizziness"], ["Moderate","Requires change in therapy","Rash, vomiting"], ["Severe","Life-threatening, hospitalization required","SJS, Anaphylaxis, Agranulocytosis"], ], col_widths=[1.6*cm, 3.5*cm, 4.4*cm]), Spacer(1,6), Paragraph(bold("Important ADR Examples"), H2), std_table(["Drug","ADR"],[ ["ACE inhibitors","Dry cough (↑ bradykinin)"], ["Aminoglycosides","Nephrotoxicity, Ototoxicity"], ["Chloramphenicol","Aplastic anemia, Grey baby syndrome"], ["Metformin","Lactic acidosis"], ["Statins","Myopathy, Rhabdomyolysis"], ["Quinolones","Tendon rupture, QT prolongation"], ["Clozapine","Agranulocytosis"], ["Halothane","Hepatitis"], ["Sulfonamides","Stevens-Johnson syndrome"], ], col_widths=[3.5*cm, 6.0*cm]), ] )) story.append(Spacer(1,4)) story.append(two_col( [ Paragraph(bold("Pharmacovigilance"), H2), bullet("Science of monitoring drug safety post-marketing"), bullet("<b>Yellow Card</b> (UK), <b>MedWatch</b> (USA), <b>PVPI</b> (India)"), bullet("<b>Naranjo Algorithm</b>: assesses causality — Definite / Probable / Possible / Doubtful"), ], [ Paragraph(bold("Factors Predisposing to ADRs"), H2), bullet("Age extremes (neonates, elderly — altered PK/PD)"), bullet("Renal/hepatic impairment"), bullet("Polypharmacy (drug interactions)"), bullet("Genetic polymorphisms (G6PD deficiency, slow/fast acetylators)"), bullet("Previous history of drug allergy"), ] )) # ── FOOTER ──────────────────────────────────────────────────────────────────── story.append(Spacer(1, 12)) story.append(HRFlowable(width="100%", thickness=1, color=DARK_BLUE)) story.append(Spacer(1, 4)) story.append(Paragraph( "<i>References: Katzung's Basic & Clinical Pharmacology 16e | Goodman & Gilman's Pharmacological Basis of Therapeutics | KD Tripathi's Essentials of Medical Pharmacology</i>", SMALL )) # ─── BUILD PDF ──────────────────────────────────────────────────────────────── doc.build(story) print(f"PDF generated: {out_path}") PYEOF echo "Script written"

Running Command

cd /tmp/workspace/pharmacology-cheatsheet && python gen_pdf.py 2>&1

Running Command

ls -lh /tmp/workspace/pharmacology-cheatsheet/General_Pharmacology_Cheatsheet.pdf

Your PDF cheat sheet is ready! Here is what's included:

General Pharmacology Cheatsheet

PDF Document · PDF


What's in the PDF (6 pages, A4, print-ready):
  • Color-coded section headers for all 16 topics
  • Structured tables for routes of administration, teratogenic drugs, TDM ranges, FDC examples, clinical trial phases, ADR classification, and more
  • ASCII diagrams for:
    • Dose-response curves (competitive vs non-competitive antagonism)
    • Plasma concentration-time curves (bioavailability)
    • TDDS transdermal patch structure
    • First order vs zero order kinetics graphs
    • Omeprazole mechanism flowchart
    • Half-life and steady-state accumulation diagrams
    • Therapeutic window diagram
  • Highlighted boxes for exam-critical points, warnings (Phenytoin, protein binding caveat), and mnemonics
  • Two-column layout throughout to maximize information density
  • References to Katzung, Goodman & Gilman, and KD Tripathi at the footer

Now answer the ANS part

Finding Sources
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Reading File
Reading File
All 14 ANS topics are covered. Here's a quick orientation guide:

Quick Exam Orientation - ANS Topics Covered

Cholinergic / Parasympathetic (5 topics):
  • ANS-C1 Organophosphorus Poisoning - SLUDGE symptoms, Atropine (muscarinic antidote) + Pralidoxime (AChE reactivator, before aging)
  • ANS-C2 Myasthenia Gravis - anti-AChR antibodies, Pyridostigmine (drug of choice), crisis management
  • ANS-C3 Anticholinesterases - Classification (reversible: Edrophonium/Neostigmine/Pyridostigmine; irreversible: OPs) + mechanism of reversible inhibitors
  • ANS-C4 Anticholinergic Drugs - Classification + mnemonic "Can't See/Spit/Pee/Shit/Sweat"
  • ANS-C5 Uses of Atropine - dose-dependent effects + all clinical uses
Adrenergic / Sympathetic (9 topics):
  • ANS-A1 Adrenaline - receptor-wise actions + all therapeutic uses including anaphylaxis, cardiac arrest, LA adjuvant
  • ANS-A2 Dopamine - dose-dependent effects (low D1/renal, mid β1/inotrope, high α1/pressor) + clinical uses
  • ANS-A3 Alpha Blockers - classification (Phentolamine, Prazosin, Tamsulosin) + uses including BPH, pheochromocytoma, hypertension
  • ANS-A4 Nitrates + Beta-Blockers in Angina - mechanism diagrams, nitrate tolerance, synergistic combination
  • ANS-A5 Cardiac + Non-cardiac Uses of Beta-Blockers - full classification table
  • ANS-A6 Propranolol - cardiac + non-cardiac uses with doses
  • ANS-A7 Open Angle Glaucoma - prostaglandin analogues (first-line), Timolol, Pilocarpine, Acetazolamide
  • ANS-A8 Acute Congestive Glaucoma - emergency: Acetazolamide IV + Mannitol → Pilocarpine → Laser iridotomy
  • ANS-A9 BPH - alpha-blockers (dynamic, fast) vs 5α-reductase inhibitors (static, slow) + combination therapy
High-yield exam tip: OP poisoning management (Atropine + Pralidoxime), MG treatment (Pyridostigmine), beta-blocker classification, and glaucoma drug mechanisms are the most frequently tested questions in this section.
This is a shared conversation. Sign in to Orris to start your own chat.